If so, then I was right to suspect that data lock was not really data lock because sequencing the samples after October 5, 2020 would involve generating new data post data lock.
HappyLibrarian,
I don't agree!
Northwest Biotherapeutics, Inc Annual Shareholder Meeting Saturday, April 18, 2020 Linda Powers:
“Additionally during this time, we’ve been working on making the data collection as comprehensive as we can. For example, in regard to certain genetic analyses, one that folks have asked us a lot about, I mean everybody knows we’ve been gathering the data on MGMT methylation status. Another genetic measure that folks have asked us quite a bit whether we will be including is IDH mutation status. There have been challenges because of a lot of the bio samples that we’ve collected we collected years ago in the trial. However, I’m happy to say that we have identified a method that we believe will enable us to include the IDH mutation status that effort is underway at present it looks like it will be doable even on bio samples from years ago. And it looks like it will be doable in the same timeframe as the anticipated datalock. So, we’re very happy about that and I’m happy to answer that question that a lot of people have had. The IDH mutation status was a completely unknown factor when our trial started and throughout much of the trial period. But in recent years has come to be recognized as very important in Glioblastoma. So we are continuing with the data collection and anticipate that the datalock will be approximately at the end of May.
You were not right. Instead, data lock was data lock. They identified IDH breakdown before entering data lock. I hope you understand the magnitude of that, and how it relates to yesterday’s WHO’s CNS tumor classification publication release that includes the redefinition of GBM.